Fig. 4: Comparison of empagliflozin versus placebo for outcomes by LVEF subgroups in patients with LVEF ≥ 50%. | Nature Medicine

Fig. 4: Comparison of empagliflozin versus placebo for outcomes by LVEF subgroups in patients with LVEF ≥ 50%.

From: Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Fig. 4

Effects are shown for the first event of cardiovascular (CV) death or hospitalization for heart failure (HHF), first HHF, CV death and total HHF (a), and the slope of change in eGFR (b) for patients in subgroups of LVEF from 50% to 70%. Data for the clinical events are presented as point estimates and 95% confidence intervals (CIs); data for the difference in slope of eGFR are presented as mean values and 95% CIs.

Back to article page